Alnylam Pharmaceuticals
ALNY
#610
Rank
โ‚น3.844 T
Marketcap
โ‚น28,811
Share price
-3.27%
Change (1 day)
45.36%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): โ‚น163.77

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น167.47. In 2023 the company made an earnings per share (EPS) of -โ‚น328.43 an increase over its 2022 EPS that were of -โ‚น864.34.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น163.77
2023-โ‚น328.43-62%
2022-โ‚น864.3429.03%
2021-โ‚น669.89-3.36%
2020-โ‚น693.15-8.48%
2019-โ‚น757.357.67%
2018-โ‚น703.3839.74%
2017-โ‚น503.3512.94%
2016-โ‚น445.6638.84%
2015-โ‚น320.99-32.88%
2014-โ‚น478.23259.44%
2013-โ‚น133.05-31.25%
2012-โ‚น193.52

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น669.89 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น192.14 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น4,012 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น254.93-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น67.92-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น22.33-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น115.37-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น32.56-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA